Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively with tumors and deliver mRNA therapy with minimal off-target effects.
(Nanowerk Spotlight) Messenger RNA can instruct cells to produce virtually any protein, making it a powerful tool for medicine. But mRNA molecules degrade within minutes in the bloodstream, destroyed by enzymes before reaching target cells. The COVID-19 pandemic demonstrated a solution: lipid nanoparticles, tiny fat-based bubbles that encapsulate and protect mRNA, enabled rapid deployment of vaccines instructing human cells to produce viral proteins.
That success, however, obscured a stubborn limitation. Lipid nanoparticles work adequately for vaccines, where generating any immune response suffices, but they fail as precision instruments for treating diseases like cancer.
The problem lies in how cells absorb these particles. Lipid nanoparticles enter cells through endocytosis, a process where the cell membrane wraps around the particle and pulls it into an internal compartment. These compartments then fuse with lysosomes, acidic organelles packed with digestive enzymes. Studies estimate that >96% of mRNA delivered this way never escapes lysosomal destruction. <4% reaches the cytoplasm, the cellular interior where mRNA must arrive to direct protein production.
As previously discussed in our Nanowerk Spotlight coverage of RNA nanotechnology, the biggest challenge in developing successful RNA therapies remains targeted delivery. Some researchers have looked to viruses for inspiration. Influenza, HIV, and other enveloped viruses bypass the lysosomal trap by fusing their outer membrane directly with the host cell membrane, releasing genetic material straight into the cytoplasm.
Synthetic carriers replicating this fusion mechanism could theoretically achieve near-complete delivery. But fusogenic carriers introduce a new problem: they fuse indiscriminately with any cell they contact, damaging healthy tissues alongside diseased ones. Attaching antibodies or other targeting molecules has shown limited success in restricting where fusion occurs.
What researchers have largely overlooked is the mechanical dimension of membrane fusion. Two lipid bilayers cannot merge without significant deformation. They must bend, form a connecting stalk, and open a pore. Each step requires overcoming an energy barrier that depends critically on membrane stiffness. Viruses exploit this physics during maturation by remodeling their lipid composition to reduce membrane rigidity, lowering the energy needed to merge with host cells. Research has shown that antiviral agents stiffening host cell membranes can block infection by raising this barrier.
Cancer cells have distinctly soft membranes. Their lipid bilayers contain elevated levels of unsaturated fatty acids, which introduce kinks in molecular chains and reduce packing density. This makes cancer cell membranes more fluid than those of healthy cells, including immune cells that patrol tissues.
A research article published in Advanced Materials (“Stiffness‐Gated Cytoplasmic mRNA Delivery Through Engineered Membrane Fusion for Breast Cancer Immunotherapy”) by investigators at Xidian University in China leverages this mechanical difference for selective mRNA delivery. The team engineered nanoparticles that fuse preferentially with soft cancer cell membranes while failing to fuse with stiffer healthy cells. When these particles encounter rigid membranes, cells absorb them through conventional endocytosis and the cargo degrades. The system transforms what was previously a drawback into a built-in safety mechanism.
(a) PGC@FM is synthesized stepwise: p53-mRNA binds G0-C14 via electrostatic interaction to form GC nanoparticles. These and PLGA are cross-linked by emulsification–solvent evaporation to make PGC particles, which are then functionalized with either native 4T1 cell membranes (4T1-CM) or 4% glycerol-modified fusion membranes (4T1-FM) to form PGC@M or PGC@FM, respectively, integrating gene loading, polymer encapsulation, and targeted modification. (b) PGC@FM achieves tumor-specific delivery via biomechanically enhanced membrane fusion. It binds 4T1 cells via adhesion molecules and homing proteins. Its low-stiffness membrane with unsaturated fatty acids promotes fusion by increasing lipid interaction sites and reducing the fusion energy barrier, delivering p53-mRNA to suppress tumors. Non-targeted particles are endocytosed and degraded by lysosomes, minimizing off-target effects. (Image: Reproduced with permission from Wiley-VCH Verlag) (click on image to enlarge)
The delivery platform, designated PGC@FM, assembles in layers. A biodegradable polymer core made of poly(lactic-co-glycolic acid) provides structural stability. Within this core sit complexes of therapeutic mRNA bound to a positively-charged dendrimer molecule called G0-C14, which condenses the genetic cargo.
The outer coating consists of membrane material harvested from 4T1 mouse breast cancer cells pre-treated with 4% glycerol. This exposure triggers lipid remodeling by upregulating enzymes involved in fatty acid desaturation, enriching the membrane with unsaturated lipids that reduce its stiffness.
The researchers validated the stiffness-fusion relationship through multiple approaches. Artificial vesicles with varying cholesterol content showed that soft vesicles fused readily with fusion-promoting liposomes while rigid vesicles with 50% cholesterol exhibited near-zero fusion.
Molecular dynamics simulations provided mechanistic detail. Soft nanoparticles composed of unsaturated lipids and the omega-3 fatty acid docosahexaenoic acid achieved complete fusion with a model membrane within 10 000 nanoseconds. Rigid particles containing saturated lipids remained entirely separate, showing binding energy roughly 860 times weaker.
At the cellular level, 4% glycerol treatment produced the greatest membrane fluidity in 4T1 cells. Fusion experiments using peptides that force adjacent membranes together revealed striking selectivity. Softened cancer cells fused with other cancer cells at 68.5% efficiency, compared to 23.6% for untreated cancer cells and <3% for macrophages and dendritic cells.
The assembled PGC@FM nanoparticles achieved 81.6% fusion efficiency with 4T1 cancer cells. Atomic force microscopy confirmed their reduced stiffness at 181 piconewtons, roughly four times softer than the 666 piconewtons measured for particles coated with unmodified membranes.
Functional tests demonstrated therapeutic potential. Nanoparticles loaded with mRNA encoding green fluorescent protein achieved transfection in cancer cells 5.2 times higher than standard lipid nanoparticles, with almost no expression in immune cells.
When loaded with mRNA encoding the tumor suppressor p53, which many cancers lack, PGC@FM delivered cargo to tumors in Balb/c mice at 4.2 times the efficiency of lipid nanoparticles. The team tested both subcutaneous tumor implants and orthotopic breast tumors, finding substantial tumor shrinkage in both models. Treated animals showed increased infiltration of cytotoxic T cells and elevated inflammatory cytokines, indicating enhanced anti-tumor immune responses.
The selective fusion mechanism introduces a new design principle for targeted drug delivery. Traditional approaches function like molecular keys fitted to specific locks on cell surfaces. This system exploits membrane stiffness, a biophysical property differing systematically between malignant and healthy tissue.
Whether the strategy generalizes across cancer types remains uncertain, since membrane properties vary among tumors. The researchers note that the stiffness-gating concept could extend to synthetic nanoparticles whose mechanical properties can be tuned through compositional adjustments. By demonstrating that physical characteristics of delivery vehicles can determine cellular selectivity, the work opens an underexplored avenue for improving both safety and efficacy of mRNA therapeutics.
For authors and communications departmentsclick to open
Lay summary
Prefilled posts
Nanowerk Newsletter
Get our Nanotechnology Spotlight updates to your inbox!
Thank you!
You have successfully joined our subscriber list.
Become a Spotlight guest author! Join our large and growing group of guest contributors. Have you just published a scientific paper or have other exciting developments to share with the nanotechnology community? Here is how to publish on nanowerk.com.
